Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine

NCT ID: NCT06997562

Last Updated: 2025-05-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-05-01
• Study Completion Date: 2025-05-03

Brief Summary

This study compares the effectiveness of greater occipital nerve blockade and sphenopalatine ganglion blockade in reducing headache intensity, duration, frequency, and disability in patients with episodic migraine.

Detailed Description

Migraine is a chronic neurological disorder characterized by recurrent headaches, affecting millions globally. Peripheral nerve blocks such as Greater Occipital Nerve (GON) and Sphenopalatine Ganglion (SPG) blockade have emerged as promising non-pharmacologic treatments.

Conditions

Greater Occipital Nerve Block; Sphenopalatine Ganglion Block; Episodic Migraine

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Greater occipital nerve blockade group

Patients will receive greater occipital nerve blockade using 2 mL of 2% lidocaine at the medial one-third of the line between the occipital protuberance and mastoid process.

Group Type: EXPERIMENTAL

Greater occipital nerve blockade

Intervention Type: OTHER

Patients will receive greater occipital nerve blockade using 2 mL of 2% lidocaine at the medial one-third of the line between the occipital protuberance and mastoid process.

Sphenopalatine ganglion blockade group

Patients will receive greater sphenopalatine ganglion blockade using 2 mL of 2% lidocaine using a transnasal approach with a cotton swab inserted along the superior middle turbinate to the posterior nasopharyngeal wall.

Group Type: EXPERIMENTAL

Sphenopalatine ganglion blockade

Intervention Type: OTHER

Patients will receive greater sphenopalatine ganglion blockade using 2 mL of 2% lidocaine using a transnasal approach with a cotton swab inserted along the superior middle turbinate to the posterior nasopharyngeal wall.

Interventions

Greater occipital nerve blockade

Patients will receive greater occipital nerve blockade using 2 mL of 2% lidocaine at the medial one-third of the line between the occipital protuberance and mastoid process.

Intervention Type: OTHER

Sphenopalatine ganglion blockade

Patients will receive greater sphenopalatine ganglion blockade using 2 mL of 2% lidocaine using a transnasal approach with a cotton swab inserted along the superior middle turbinate to the posterior nasopharyngeal wall.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Adults aged 18-65 years.
• Both sexes.
• Diagnosed with episodic migraine per the International Classification of Headache Disorders, 3rd edition (ICHD-3).
• Failure to achieve adequate relief with at least one prophylactic migraine treatment.

Exclusion Criteria

• Chronic migraine (≥15 headache days per month).
• History of nerve blocks within the last 6 months.
• Known allergy to anesthetic agents.
• Pregnancy or lactation.
• Active psychiatric conditions affecting compliance.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

New Valley University

OTHER

Sponsor Role: lead

Responsible Party

Ahmed Omar Twaisy

Lecturer of Anesthesia and Intensive Care, Faculty of Medicine, New Valley University, Egypt.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

New Valley University

New Valley, New Valley Governorate, Egypt

Countries

Egypt

Other Identifiers

20250430007

Identifier Type: -

Identifier Source: org_study_id